Cent Leads AI Health Revolution: Early Disease Detection Secures Major Funding
March 12, 2026, 3:35 pm
Cent, a new healthtech startup, secures funding for its AI-driven early disease detection platform. Co-founded by Practo's Shashank ND, Cent targets critical conditions like cancer, cardiac, and metabolic diseases. It identifies these often-fatal conditions before symptoms manifest. The platform employs advanced multi-modal screening, including MRI and genomics, alongside powerful AI analysis. A direct-to-consumer model ensures broad access. Cent's approach promises to revolutionize preventive healthcare. The company plans rapid expansion across India and eventual global reach. Investor confidence is high. This innovative, proactive strategy saves lives and reduces healthcare burdens, marking a significant shift in health management paradigms.
Cent recently secured significant funding. The investment fuels its groundbreaking AI-driven platform. Cent focuses on early disease detection. Practo founder Shashank ND co-founded the venture. Arpit Garg and Anshul Khandelwal joined as co-founders. Investors include OneFlow Holdings, Shashank ND's family office. Venture firm South Park Commons also participated. The funding amount remains undisclosed. This capital propels Cent's critical mission.
Cent directly confronts a major global health crisis. Life-threatening diseases, often silent, cause millions of deaths. Cancer, cardiac conditions, and metabolic disorders represent the highest mortality. They account for over 70% of global fatalities. Symptoms often appear too late. Conventional checkups frequently miss crucial early indicators. Cent aims to fundamentally shift this approach. It champions detection *before* any symptoms manifest. This proactive stance promises to save countless lives.
Cent developed a unique, proprietary screening protocol. It is named CCNM. This acronym signifies cardiac, cancer, neurological, and metabolic. The protocol integrates a suite of advanced diagnostic tools. Full body MRI scans form a cornerstone. Cardiac CT and ECG provide detailed heart health data. DEXA scans accurately assess bone density and body composition. The system analyzes over 120 distinct blood and urine biomarkers. Comprehensive genomic testing offers deep individual insights.
Artificial intelligence forms the core of data processing. AI algorithms meticulously analyze vast datasets. They identify minute patterns and subtle anomalies. These findings often elude human observation alone. Expert radiologists and specialized physicians then review the AI-generated insights. This combined approach ensures accuracy. A comprehensive, organ-level health report is produced. Reports can span 60 to 70 pages. Each organ receives a dedicated health score. This provides a holistic, detailed health snapshot for every individual.
Cent operates a direct-to-consumer (D2C) business model. This distinguishes it in the Indian healthcare landscape. Many healthcare companies typically serve institutions. They target hospitals, insurers, or corporate clients. Cent generates revenue directly from individual consumers. This model eliminates intermediary commissions. It avoids financial ties to hospitals, doctors, or insurance providers. Such transparency aligns Cent's interests solely with patient wellness. It fosters greater trust and accessibility for its users.
The Bengaluru-based startup commenced operations in Q1 FY26. It has already completed over 1,500 full body scans. Initial results underscore its profound impact. Approximately 26% of all scans reveal clinically meaningful findings. More critically, 3-4% identify severe conditions. These include early-stage cancers or significant heart blockages. Many individuals with these critical findings reported no prior symptoms. This highlights Cent's robust preventive strength.
Cent quantifies its effectiveness through a unique metric. It calls this the Early Detection Index (EDI). The company proudly claims an EDI score of about 83%. This starkly contrasts with conventional annual health checkups. Traditional screenings typically achieve only 15-20% EDI. Cent's superior protocol demonstrably improves the chances of early disease diagnosis. This index validates its innovative approach and effectiveness.
The company's genesis stems from personal tragedy. Both Shashank ND and Anshul Khandelwal lost family members. Cancer claimed their loved ones. These experiences highlighted a critical flaw. Despite medical advances, diseases were often detected too late. The founders recognized a profound gap. Existing preventive healthcare infrastructure was inadequate for true proactive screening. Cent was specifically designed to close this detection gap. It offers dedicated technology and rigorous protocols.
Investor confidence in preventive health solutions is escalating. This trend reflects a growing recognition. Non-communicable diseases impose a heavy burden globally. AI's disruptive potential in medical diagnostics is undeniable. India’s current healthcare spending is modest. It represents about 3% of its GDP. This creates a vast untapped market for innovative solutions. Cent is positioned to lead this expansion and capitalize on the rising demand for proactive health management.
Cent showcases remarkable operational growth. It reports a 50% month-on-month expansion rate. The annualized revenue run rate (ARR) already reached $2 million. This robust financial performance attracts further investment interest. It validates the market demand for Cent's services. This sustained growth signals a successful business model and a strong future outlook for the company.
The recent capital injection facilitates ambitious expansion plans. Cent intends to establish dedicated early detection centers. These centers will span major Indian cities. Bengaluru will host the inaugural facility. It opens in April. Mumbai, Delhi, and Hyderabad will follow swiftly. These strategic locations will bring advanced diagnostics and preventive health services to large urban populations.
Cent anticipates a substantial Series A funding round. This next stage capital will be significantly larger. It aims for 5-6 times the seed round's size. This investment will accelerate network expansion. It will also fund initial international market entry. Cent actively collaborates with global imaging equipment manufacturers. It optimizes cutting-edge MRI systems for preventive screening applications. This ensures access to the latest diagnostic technologies.
Cent is not alone in this innovative space. Globally, a new wave of healthtech startups emerges. Companies like Prenuvo, Function Health, and Neko Health also build AI-led preventive platforms. They integrate advanced diagnostics for early detection. This broader trend underscores the global shift. Proactive health management is gaining significant traction worldwide. The oncology sector in India also sees increased investment. Recent funding rounds for Oncare, 4baseCare, MOC Cancer Care, and Everhope Oncology highlight this. A strong market for early disease intervention is clearly developing.
Cent embodies a pivotal transformation. It shifts healthcare from reactive treatment to proactive prevention. The convergence of AI and advanced diagnostics offers new hope. Early detection undeniably saves lives. It significantly reduces long-term healthcare expenditures and societal burdens. Cent stands at the forefront of this vital revolution. Its long-term impact on global health and individual well-being will be profound.
Cent recently secured significant funding. The investment fuels its groundbreaking AI-driven platform. Cent focuses on early disease detection. Practo founder Shashank ND co-founded the venture. Arpit Garg and Anshul Khandelwal joined as co-founders. Investors include OneFlow Holdings, Shashank ND's family office. Venture firm South Park Commons also participated. The funding amount remains undisclosed. This capital propels Cent's critical mission.
Cent directly confronts a major global health crisis. Life-threatening diseases, often silent, cause millions of deaths. Cancer, cardiac conditions, and metabolic disorders represent the highest mortality. They account for over 70% of global fatalities. Symptoms often appear too late. Conventional checkups frequently miss crucial early indicators. Cent aims to fundamentally shift this approach. It champions detection *before* any symptoms manifest. This proactive stance promises to save countless lives.
Cent developed a unique, proprietary screening protocol. It is named CCNM. This acronym signifies cardiac, cancer, neurological, and metabolic. The protocol integrates a suite of advanced diagnostic tools. Full body MRI scans form a cornerstone. Cardiac CT and ECG provide detailed heart health data. DEXA scans accurately assess bone density and body composition. The system analyzes over 120 distinct blood and urine biomarkers. Comprehensive genomic testing offers deep individual insights.
Artificial intelligence forms the core of data processing. AI algorithms meticulously analyze vast datasets. They identify minute patterns and subtle anomalies. These findings often elude human observation alone. Expert radiologists and specialized physicians then review the AI-generated insights. This combined approach ensures accuracy. A comprehensive, organ-level health report is produced. Reports can span 60 to 70 pages. Each organ receives a dedicated health score. This provides a holistic, detailed health snapshot for every individual.
Cent operates a direct-to-consumer (D2C) business model. This distinguishes it in the Indian healthcare landscape. Many healthcare companies typically serve institutions. They target hospitals, insurers, or corporate clients. Cent generates revenue directly from individual consumers. This model eliminates intermediary commissions. It avoids financial ties to hospitals, doctors, or insurance providers. Such transparency aligns Cent's interests solely with patient wellness. It fosters greater trust and accessibility for its users.
The Bengaluru-based startup commenced operations in Q1 FY26. It has already completed over 1,500 full body scans. Initial results underscore its profound impact. Approximately 26% of all scans reveal clinically meaningful findings. More critically, 3-4% identify severe conditions. These include early-stage cancers or significant heart blockages. Many individuals with these critical findings reported no prior symptoms. This highlights Cent's robust preventive strength.
Cent quantifies its effectiveness through a unique metric. It calls this the Early Detection Index (EDI). The company proudly claims an EDI score of about 83%. This starkly contrasts with conventional annual health checkups. Traditional screenings typically achieve only 15-20% EDI. Cent's superior protocol demonstrably improves the chances of early disease diagnosis. This index validates its innovative approach and effectiveness.
The company's genesis stems from personal tragedy. Both Shashank ND and Anshul Khandelwal lost family members. Cancer claimed their loved ones. These experiences highlighted a critical flaw. Despite medical advances, diseases were often detected too late. The founders recognized a profound gap. Existing preventive healthcare infrastructure was inadequate for true proactive screening. Cent was specifically designed to close this detection gap. It offers dedicated technology and rigorous protocols.
Investor confidence in preventive health solutions is escalating. This trend reflects a growing recognition. Non-communicable diseases impose a heavy burden globally. AI's disruptive potential in medical diagnostics is undeniable. India’s current healthcare spending is modest. It represents about 3% of its GDP. This creates a vast untapped market for innovative solutions. Cent is positioned to lead this expansion and capitalize on the rising demand for proactive health management.
Cent showcases remarkable operational growth. It reports a 50% month-on-month expansion rate. The annualized revenue run rate (ARR) already reached $2 million. This robust financial performance attracts further investment interest. It validates the market demand for Cent's services. This sustained growth signals a successful business model and a strong future outlook for the company.
The recent capital injection facilitates ambitious expansion plans. Cent intends to establish dedicated early detection centers. These centers will span major Indian cities. Bengaluru will host the inaugural facility. It opens in April. Mumbai, Delhi, and Hyderabad will follow swiftly. These strategic locations will bring advanced diagnostics and preventive health services to large urban populations.
Cent anticipates a substantial Series A funding round. This next stage capital will be significantly larger. It aims for 5-6 times the seed round's size. This investment will accelerate network expansion. It will also fund initial international market entry. Cent actively collaborates with global imaging equipment manufacturers. It optimizes cutting-edge MRI systems for preventive screening applications. This ensures access to the latest diagnostic technologies.
Cent is not alone in this innovative space. Globally, a new wave of healthtech startups emerges. Companies like Prenuvo, Function Health, and Neko Health also build AI-led preventive platforms. They integrate advanced diagnostics for early detection. This broader trend underscores the global shift. Proactive health management is gaining significant traction worldwide. The oncology sector in India also sees increased investment. Recent funding rounds for Oncare, 4baseCare, MOC Cancer Care, and Everhope Oncology highlight this. A strong market for early disease intervention is clearly developing.
Cent embodies a pivotal transformation. It shifts healthcare from reactive treatment to proactive prevention. The convergence of AI and advanced diagnostics offers new hope. Early detection undeniably saves lives. It significantly reduces long-term healthcare expenditures and societal burdens. Cent stands at the forefront of this vital revolution. Its long-term impact on global health and individual well-being will be profound.